Company intelligence / Profile preview
IBSA Pharma
Antibes, Provence-Alpes-Côte d'Azur, France
- Ownership
- Private
- Development stage
- Other
01
Overview
One approved small molecule drug (diclofenac epolamine) targeting COX-1 and COX-2 for acute pain, plus clinical-stage programs in dermatology, diabetic wound repair, psoriasis, and other areas[5]. Continually launches new products such as skin repair and filler devices[4]. Clinical trials include randomized and controlled studies for medical devices and dermatological treatments[5].
- Therapeutic areas
- ImmunologyEndocrinologyRheumatologyDermatologyNeurology
- Modalities
- Small moleculeMedical deviceCosmeticFood supplement
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
IBSA Institut Biochimique (historical distributor/acquirer)
Beyond the preview
Go deeper on IBSA Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBSA Pharma.